LGT Fund Management Co Ltd. Has $2.79 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

LGT Fund Management Co Ltd. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 49.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 14,200 shares of the medical research company's stock after selling 14,003 shares during the period. LGT Fund Management Co Ltd.'s holdings in IQVIA were worth $2,790,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. US Bancorp DE increased its holdings in IQVIA by 62.2% in the third quarter. US Bancorp DE now owns 27,061 shares of the medical research company's stock valued at $6,413,000 after purchasing an additional 10,379 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of IQVIA by 35.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company's stock valued at $96,000 after acquiring an additional 106 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of IQVIA in the 3rd quarter valued at approximately $218,000. Optas LLC acquired a new position in IQVIA during the third quarter valued at approximately $210,000. Finally, Conning Inc. bought a new stake in IQVIA in the third quarter valued at approximately $206,000. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IQV. Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Stock Performance

NYSE:IQV traded down $0.40 during mid-day trading on Thursday, hitting $185.45. The stock had a trading volume of 1,211,035 shares, compared to its average volume of 1,208,570. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.70 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 1.99 and a beta of 1.50. The company's 50 day simple moving average is $198.24 and its 200 day simple moving average is $213.66.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.